The manufacturing plant, which will be located in Aurangabad in Maharashtra will produce 40 billion capsules per year.
ACG (Mumbai, India) has signed a memorandum of understanding (MoU) with the government of the state of Maharashtra in India to set up what ACG says would be Asia’s largest manufacturing plant and research & development center. The manufacturing plant, which will be located in Aurangabad in Maharashtra will produce 40 billion capsules per year and serve both Indian and international pharmaceutical and nutraceutical companies.
“Our vision to be a future-ready solutions provider to the pharma industry anywhere in the world and our proposed investment of approximately USD$ 100 million (over INR 600 crores) in this state-of-the-art plant, is an integral part of ACG’s mission to double our capsule manufacturing capacity to 240 billion capsules a year,” said Karan Singh, managing director for ACG, in a press release. “This plant will play a key role in further cementing India’s position as the global hub of capsule manufacturing and will add to improved access to high quality, safe and affordable medicines and nutraceuticals globally.”
The plant will also employ key design principles from the internationally recognized Leadership in Energy and Environmental Design (LEED) and will be powered significantly by renewable energy. Setting new benchmarks for the industry, the plant will employ automation and industry 4.0 technologies to minimize resource intensity and ensure products meet and exceed the highest global manufacturing practices.
“We have a long history of operating in Maharashtra and are privileged to sign this MoU with Government of Maharashtra for this mega project which when ready by 2023 will create around 1000 direct and indirect jobs in the region,” said Nitin Desai, senior vice president for ACG.